Assorted News from the Last Week: The FDA Pediatric ODAC met to “discuss perspectives on the impact of FDARA on the field of pediatric oncology,
Assorted News from the Last Week: St. Jude survivorship portal and its ability to facilitate breakthroughs in pediatric cancer survivorship research were published recently in Cancer
Assorted News from the Last Week: To understand how CNS tumors impact the AYA population, NCI-CONNECT (Comprehensive Oncology Network Evaluating Rare CNS Tumors), the Central
Assorted News from the Last Week: Brain cancer in children is notoriously hard to treat – a new mRNA cancer vaccine triggers an attack from
Assorted News from the Last Week: Congratulations to CAC2 Supporting Organization Day One Biopharmaceuticals. The FDA has granted accelerated approval to tovorafenib (Ojemda) for the
Assorted News from the Last Week: To achieve successful socioeconomic reintegration in the long term, it is crucial to implement a childhood cancer survivorship program
Assorted News from the Last Week: The UK’s National Institute for Health and Care Excellence (NICE) recommended Novartis’ autologous CAR T-cell therapy Kymriah (tisagenlecleucel) for
Assorted News from the Last Week: FDA announced its Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee will meet virtually on 22 May to
Assorted News from the Last Week: Cancer is far more likely to be caused by “tumor-suppressor” genes than by one gene run amok. Interestingly, last
Assorted News from the Last Week: The White House Office of Science and Technology Policy (OSTP) has announced that the Pediatric Cancer Data Commons (PCDC)
